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Abstract: Recurrence of endometriosis after surgery constitutes a serious challenge. Whether there is
an evolution of lesion subtypes with each recurrence and whether certain lesions subtypes tend to recur
faster than others is not adequately addressed. Medical records of all patients who underwent surgery
for endometriosis between 1997 and 2018 in the Department of Gynecology and Obstetrics, University
of Bern, were reviewed. Inclusion criteria was surgically confirmed endometriosis recurrence, defined
as a subsequent surgery for endometriosis after a previous complete surgical excision of endometriosis
lesions. Three subtypes of endometriosis were defined: superficial peritoneal endometriosis (SUP),
ovarian endometrioma (OMA), and deep infiltrating endometriosis (DIE). Time to recurrence and
variation in endometriosis subtype between the first and recurrent surgeries were the primary
outcome measures. Out of the 322 patients with recurrent surgery that were identified, for 234 of
them, the endometriosis subtype at first surgery was confirmed and classified (SUP = 56, OMA = 124,
DIE = 54). No statistically significant difference was found for time to recurrence between lesion
subtypes. SUP compared to the other groups had a higher possibility of presenting with SUP at
recurrence (Odds Ratio (OR): 3.65, 95% confidence interval (CI): 1.74–7.51) and OMA compared
to the other groups had a higher possibility of presenting with OMA at recurrence (OR: 3.72, 95%
CI: 2.04–6.74). Nevertheless, a large number of SUP patients subsequently presented with OMA
(10/56: 17.9%) or DIE (27/56: 48.2%) lesions at recurrence. Similarly, a large number of OMA patients
subsequently presented with DIE (49/124: 39.5%) lesions at recurrence. In conclusion, although
SUP and OMA patients compared to the others are more likely to present with the same subtype at
recurrence, increasing lesion subtype severity occurs in a substantial proportion of patients. Time to
recurrence is independent from the lesion subtype at first surgery.
Keywords: recurrence; progression; peritoneal endometriosis; endometrioma; deep-infiltrative
endometriosis
1. Introduction
Endometriosis, characterized by the growth of endometrial-like tissue outside the uterine
cavity, is a highly prevalent gynecological disorder of reproductive-aged women worldwide [1–3].
It is a significantly heterogeneous disease, both in phenotype and clinical outcomes that can lead
to a significant reduction in quality of life and work productivity [4,5]. Recommended treatments
for endometriosis are either hormonal-based therapy or laparoscopic surgical excision depending on
response and tolerability to medical treatment, as well as family planning.
J. Clin. Med. 2020, 9, 496; doi:10.3390/jcm9020496 www.mdpi.com/journal/jcm
J. Clin. Med. 2020, 9, 496 2 of 11
Laparoscopic surgery is associated with decreased overall pain, both at 6 and 12 months after
surgery [6]. However, despite complete removal of endometriotic tissue, a high proportion of patients
will require additional surgery due to endometriosis recurrence. In a recent UK population-based report,
48% of patients with endometriosis received surgical treatment. Approximately one-fifth of these
patients required further surgical treatment, within three years of the index procedure [7]. Other studies
have reported total recurrence rates of 21.5% and 40%–50% at two and five years, respectively [8,9].
Endometriosis lesions are a heterogenous group of lesions that are currently split into three
subtypes based on the location and infiltration depth: superficial peritoneal endometriosis (SUP),
ovarian endometrioma (OMA), and deep infiltrating endometriosis (DIE) [10,11]. Although patients
with SUP may suffer from pelvic pain, OMA and DIE generally cause heavier symptoms, have more
serious long-term complications, are more difficult to manage [12–16], and thus considered as more
severe endometriosis subtypes. Whether there is an evolution of lesion subtypes over each recurrence
and whether certain lesions subtypes recur faster than others is not adequately addressed. Research
up to now has been scant, limited to adolescence and with contradictory results [17–21].
The purpose of this study, therefore, was to characterize the lesion subtypes in first and subsequent
surgeries, examine their evolution and compare the time required for subsequent surgery based on the
initial lesion subtype.
2. Materials and Methods
The study was prepared according to the “Strengthening the reporting of observational studies
in epidemiology” guidelines [22] and was institution review board approved (no. 2017-00952).
The electronic medical records were searched for all patients who underwent at least one laparoscopic
surgery for endometriosis in the Department of Gynecology and Obstetrics, University of Bern
(between January 1997 and October 2018). The initial search for inclusion criteria was performed by one
researcher (L.M.) and the medical records identified for inclusion were reviewed by two independent
researchers (K.N.) (L.M). Only patients with more than one surgery for endometriosis were included,
while surgeries in external hospitals were not excluded. For all surgeries, either visual or histological
confirmation of endometriosis was required for inclusion. Unavailable surgical reports or undefined
surgical technique, incomplete excision of endometriosis lesions, and diagnostic surgeries made up the
exclusion criteria. Recurrence was defined as subsequent surgery for endometriosis after a previous,
complete surgical excision of endometriosis. Recurrence of endometriosis symptoms or recurrence of
endometriosis based on clinical suspicion or imaging was not evaluated.
Surgical data, histological results and time to recurrence were collected and analyzed
retrospectively. The classification of endometriosis subtype was performed according to the most
severe endometriotic lesion identified [23]. As a result, DIE with concomitant OMA and/or SUP was
classified as DIE. OMA with concomitant SUP was classified as OMA.
2.1. Surgical Technique
The standardized laparoscopic surgical technique for DIE performed in our clinic has been
described previously [24]. SUP was treated by excision via monopolar needle or scissors. OMA was
treated by the striping technique.
2.2. Statistical Analysis
Median values and range, or mean values and standard deviation (SD) were calculated for
continuous variables and percentages for the qualitative variables. The time to recurrence was assessed
according to the Kaplan-Meier life-table analysis. A log-rank test was used to compare the recurrence
rates between groups. An ordinary one-way ANOVA and Kruskal–Wallis test were used to compare
continuous parametric and nonparametric variables, respectively. Fisher’s exact test was used to
compare the proportion of endometriosis subtypes at each recurrence and to determine whether lesion
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subtype was more or less severe. Significance was set at a p value of <0.05. Statistical analysis was
carried out with GraphPad Prism version 8.0.1 (GraphPad Software, San Diego, CA 92108, USA).
3. Results
3.1. Patient Characteristics
Among 1332 patients with surgically diagnosed endometriosis, 322 satisfied both the inclusion
and exclusion criteria. For 234 (72.7%), the endometriosis subtype at first surgery was verified from the
surgical report. For the remaining 88 patients, the endometriosis subtype was unclear. The patients’
characteristics recorded at the initial surgery are summarized in Table 1.
Table 1. Patient’s characteristics according to the endometriosis subtype at first surgery.
Characteristics
First Surgery SUP OMA DIE Unknown p
(n = 56) (n = 124) (n = 54) (n = 88)
Age (y ± SD) 27.7 ± 6.4 29.4 ± 5.3 30.1 ± 5.0 29.4 ± 6.6 ns
Median time to second surgery
(min-max, months) 30.5 (5–216) 30 (6–244) 36 (4–141) 33.5 (5–190) ns
First surgery in external hospital 43 (76.8%) 109 (87.9%) 33 (61.1%) 85 (96.6%) <0.001 *
Second surgery in external hospital 12 (21.4%) 40 (32.3%) 12 (22.2%) 33 (37.5%) ns
One recurrence 100% 100% 100% 100% n/a
Two recurrences 18 (32.1%) 52 (41.9%) 18 (33.3%) 44 (50.0%) ns
Three recurrences 4 (7.1%) 16 (12.9%) 8 (14.8%) 22 (25.0%) ns
Four recurrences 2 (3.6%) 4 (3.2%) 4 (7.4%) 13 (14.8%) ns
Five recurrences 0 0 1 (1.9%) 3 (3.4%) ns
* Statistical comparison performed by Chi-square Test. Abbreviations: SUP, superficial peritoneal endometriosis;
OMA, ovarian endometrioma; DIE, deep infiltrating endometriosis; y, years; SD, standard deviation; ns, not significant.
3.2. Time to Recurrence
The median time to first recurrent surgery, irrespective of lesion subtype, was 32 months
(5–244 months) (Figure S1). For patients who underwent a second recurrent surgery, it was performed
after an additional 35 months (5–222 months). Surgery for the third and fourth recurrence were
performed after 30 (6–160 months) and 34 (5–90 months) months, respectively. The times between
surgeries for each recurrence were not statistically significantly different (Figure S2).
For patients categorized in the SUP group, based on their first surgery for endometriosis,
the median time to their first recurrence was 30.5 (5–216) months. For patients categorized in the
OMA group, this time was 30 (6–244) months and for patients categorized in the DIE group this was
36 (4–141) months. The time to recurrence for each lesion subtype was not statistically significantly
different (Figure 1).
3.3. Recurrent Endometriosis Subtype, Based on Subtype at First Surgery
Patients that had a SUP at the first surgery were more likely to present again with a SUP at
subsequent surgery (17/56: 30.4%), compared to women that originally had an OMA (10/124: 8.1%),
or women that originally had a DIE (9/54: 16.7%). This difference was statistically significant (OR: 3.65,
95% CI: 1.74–7.51; p = 0.001). Similarly, patients that had an OMA at first surgery were more likely,
to have an OMA (58/124: 46.8%) at subsequent surgery compared to women that originally had a SUP
(10/56: 17.9%), or women that had a DIE (11/54: 20.6%). This difference was statistically significant
(OR: 3.72, 95% CI: 2.04–6.74; p < 0.0001). Patients that initially presented with DIE showed a trend to
also subsequently present with DIE (29/54: 53.7%) at the next surgery. However, compared to the other
groups, it was not statistically significantly higher, reflecting the high percentage of patients from the
other groups that had DIE at subsequent surgeries (Table 2 and Figure 2).
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Table 2. Evolution of endometriosis from first to recurrent surgery.
Recurrent Surgery






















17 (30.4%) 0.001 10 (8.1%) 0.0011 9 (16.7%)
ns
30 (9–194) 3.65 28 (7–244) 0.28 31 (5–116)
(1.74, 7.51) (0.14, 0.62)














27 (48.2%) ns 49 (39.5%) ns 29 (53.7%) ns
27 (5–139) 51 (8–135) 39 (18–119)
Unknown subtype 2 (3.6%) ns 5 (4.0%) ns 5 (9.3%) ns
31.5 (12.51) 30 (12–156) 24 (4–31)
In each cell, the number of cases evolving into SUP, OMA, DIE, or unknown lesion subtype at recurrent surgery and their percentage is given. 1: The ORs in this column reflect the
possibility of a patient with initially SUP lesions compared to a patient with initially non-SUP lesions (OMA and DIE) to present a certain endometriosis lesion at recurrent surgery. The
bold numbers represent the statistically significant higher possibility of SUP patients, compared to non-SUP patients to present with SUP lesions again, in the absence of OMA and DIE at
recurrent surgery. 2: The ORs in this column reflect the possibility of a patient with initially OMA lesions compared to a patient with initially non-OMA lesions (SUP and DIE) to present a
certain endometriosis lesion at recurrent surgery. The bold marked numbers represent the statistically significant higher possibility of OMA patients, compared to non-OMA patients to
present with OMA lesions again in the absence of DIE at recurrent surgery. 3: The ORs in this column reflect the possibility of a patient with initially DIE lesions compared to a patient with
initially non-DIE lesions (SUP and OMA) to present SUP, OMA or DIE at recurrent surgery. Abbreviations: SUP, superficial peritoneal endometriosis; OMA, ovarian endometrioma; DIE,
deep infiltrating endometriosis; ns, not significant; Min-Max, Minimum-Maximum; OR (95% CI), Odds Ratio (95% Confidence Interval).
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3.4. Evolution of Endometriosis Subtypes over Recurrent Surgeries
Interestingly, although the above results suggest the lesion subtype present at the first surgery is
a good indication of the lesion to expect at the recurrent surgery, the results also show that a substantial
proportion of patients with initially SUP or OMA lesions progress to a more severe subtype at recurrence.
Of the women initially presenting with SUP, 66.1% returned for recurrent surgery with either an OMA
(10/56: 17.9%) or DIE (27/56: 48.2%), which was statistically significant more when both of these
subtypes were combined vs. SUP at recurrence (17/56: 30.4%), (p = 0.0295). Similarly, of the women
initially diagnosed with an OMA, 39.5% (49/124) returned for recurrent surgery with DIE, whereas only
8.1% (10/124) with the less severe SUP (Table 2 and Figure 2), which was also statistically significant
based on a Fisher exact test of more vs. less severe lesions (p < 0.0001).
There were two patients (3.6%) in the initially SUP group that had a concomitant hysterectomy
at recurrent surgery. One patient (1.8%) underwent hysterectomy during the first surgery, but still
required a subsequent surgery for a recurrence of OMA. Six patients (5%) in the initially OMA
group underwent a concomitant hysterectomy at recurrent surgery. Three patients (2.4%) underwent
a hysterectomy during the first surgery, all three of which had an OMA lesion at subsequent surgery,
one of which also had a DIE lesion. Eight patients (15.4%) in the DIE group underwent a concomitant
hysterectomy at the second surgery. Two patients (3.7%) underwent hysterectomy during the first
surgery and both subsequently presented with DIE at the next surgery; one of which was combined
with an OMA. Concomitant hysterectomy at recurrence was significantly more common in the DIE
compared to the SUP or OMA group (OR: 3.00, 95% CI: 1.11–7.73; p = 0.007).
The majority of the OMA identified at subsequent surgeries occurred on the same ovary as the
initial surgery (Table 3 (a)). Similarly, the majority of the patients that presented with DIE lesions at
first surgery were most likely to have recurrent lesions in the same area at the subsequent surgery
(Table 3 (b)).
Of the 322 patients that underwent at least two surgeries for endometriosis, 128 (39.8%) had an
additional 3rd surgery and 48 (14.9%) a 4th surgery. In these patients, we observed a similar trend
with a high proportion of patients presenting with more severe subtypes and in particular DIE lesions
at subsequent surgery. The data are presented in the Supplementary Table S1 (2nd to 3rd surgery) and
Table S2 (3rd to 4th surgery). The discrepancy between the above-referred total numbers of recurrences
and the numbers in the supplemental tables is due to some patients for which the lesion subtypes
could not be classified, thus not included in the tables. Due to the limited sample numbers, a statistical
analysis was not performed.
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Table 3. (a) Location analysis of OMA at first surgical recurrence. (b) Location analysis of DIE at recurrent surgery.
(a)
Location of OMA at 2nd Surgery
Location of OMA at 1st Surgery
Bilateral
n = 13 (22.4%)
Unilateral Left
n = 21 (36.2%)
Unilateral
Right
n = 14 (24.1%)
Unknown
n = 10 (17.2%)
Bilateral 6 (46.2%) 9 (42.9%) 4 (28.6%) 4 (40.0%)
Unilateral left 3 (23.1%) 8 (38.1%) 3 (21.4%) 1 (10.0%)
Unilateral right 4 (30.8%) 4 (19.0%) 7 (50.0%) 3 (30.0%)
Unknown 0 (0%) 0 (0%) 0 (0%) 2 (20.0%)
(b)

















Uterosacral ligament 0 1 (3.4%) 1 (3.4%) 1 (3.4%) 1 (3.4%) 7 (25.9%) 9 (18.4%)
Vagina 0 8 (27.6%) 5 (17.2%) 0 0 10 (37.0%) 23 (46.9%)
Intestine 1 (3.4%) 4 (13.8%) 4 (13.8%) 0 2 (6.9%) 12 (44.4%) 15 (30.6%)
Bladder 0 0 0 0 0 2 (7.4%) 3 (6.1%)
Others * 2 (6.9%) 1 (3.4%) 1 (3.4%) 0 1 (3.4%) 1 (3.7%) 5 (10.2%)
The 58 patients with OMA at first and second surgery are analyzed according to which side was involved; * umbilicus, appendix, inguina, round ligament of uterus. Note: The 105 patients
with DIE at second surgery are analyzed according to the initial lesion subtype. For 29 of them it was DIE, for 27 SUP and for 49 OMA at the first surgery. Abbreviations: SUP, superficial
peritoneal endometriosis; OMA, ovarian endometrioma; DIE, deep infiltrating endometriosis.
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4. Discussion
In the present study, we demonstrate that the time to first recurrent endometriosis surgery is
independent from the endometriosis subtype observed at the initial surgery. Moreover, at subsequent
surgery the endometriosis subtype observed is likely to be the same subtype observed previously.
Interestingly, however, there is a high percentage of patients that present with more severe lesion
subtypes, particularly DIE. The trend towards more severe endometriosis subtypes in these patients
implies disease progression may occur overtime irrespective of surgical removal.
To the best of our knowledge, this is the first study to compare the time to recurrence between
different endometriosis subtypes. The median time to first recurrence for all women with endometriosis
was 31 months, similar to the 30 months reported by Liu et al. [25].
It is important to note that our study only included patients who had recurrent endometriosis
lesions confirmed through a second surgery. We have specifically selected this cohort because (1)
we believe that given a long enough follow up there is significant potential for all women with
endometriosis to recur, and thus it becomes difficult to define a non-recurrence group, particularly
if surgery is required to confirm the diagnosis and, (2) by including women that have had an initial,
complete excision of endometriosis we can confirm that at this point in time these women were devoid
of macroscopic endometriosis lesions. This study does not report on women who did not require
subsequent surgical intervention, thus it does not describe the likelihood of all endometriosis to recur,
but rather only the time to surgical intervention for the group of women with endometriosis that
have recurrence significant enough to require additional surgical intervention. Further studies that
examine whether there are differences in recurrence in all patients, i.e., those that do not require surgical
intervention would be interesting, but challenging to design and perform.
Whether endometriosis represents a progressive disease that worsens over time is not resolved,
but is attracting more attention. A three-year prospective study suggested that endometriosis is a
progressive disease [13], which was supported by a review of adolescence endometriosis [17], with an
additional study showing development from peritoneal to ovarian endometriosis, including uterosacral
ligament lesions during a two to five year follow up [19]. On the contrary, an analysis of randomized
control studies (RCT) on adolescents showed 71% of the patients without endometriosis excision did
not progress [18]. However, a single RCT contributed the majority of cases to this analysis with a short
follow up of only four to six months [26]. The findings of our study agree with the suggestion of
progression and extend them to a broader population with a longer follow up.
OMA was the most common endometriosis subtype that was observed in this group of patients
(53.4%). With OMA being the easiest type of endometriosis to diagnose, it seems plausible that
they are more usually treated via surgery. If the higher incidence of recurrence is solely due to
an observation bias, or that OMA is more likely to recur cannot be answered by the current study.
A recent randomized controlled study evaluating levonorgestrel-IUD reported 25%–37.5% OMA
recurrence [27]. However, recurrent surgery on the ovary is related to ovarian reserve damage [28] and
recurrent surgery for endometriosis in general is related to stress, complications, as well as personal
and social costs. Therefore, caution is required firstly to adhere to the guidelines on the indications
for endometriosis surgery and surgical technique and secondly to decrease the risk of recurrence via
hormonal suppressive therapy [29–32].
The underlying pathogenesis of endometriosis recurrence is unclear. If recurrence derives from
residual endometriotic cells that remain after surgery, or from de novo lesions is a matter of debate [8].
It has been reported that DIE lesions reappeared at subsequent surgery in the same area of the pelvis
as at the previous surgery [33], possibly due to the high number of incomplete surgeries included in
the study. In another study, 50 out of 62 (80.6%) patients with recurrent endometriomas had recurrence
on the treated ovary [34]. Our study also shows that the majority of recurrent endometriomas were on
the same ovary, which could indicate residual lesions. However, lesions on the contralateral ovary,
or other areas were also observed indicating that de novo lesion development is possible especially
since some recurrences were documented after a long nascent period. Another possibility could be
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that recurrent lesions at different locations than the initial lesion could occur by endometriotic tissue
dissemination during the first surgery.
An important limiting factor in endometriosis research is that although endometriosis recurrence
can be well defined within a retrospective study, identifying and confirming non-recurrence is
impossible. Thus, no non-recurrent group of patients was included in our study. Many patients may
not undergo a subsequent surgery for endometriosis, choosing to tolerate endometriosis-associated
symptoms, or to treat the symptoms medically. A detailed follow-up including this information is
perhaps possible within a prospective study with long enough follow-up, since many recurrences occur
after 48 months or even longer. However, due to the difficulty of an accurate non-surgical diagnosis of
endometriosis the classification of a patient as non-recurrent would be challenging, even in such a
prospective follow-up study.
Based on the surgical protocols, we assumed in each case that the endometriotic lesions were
completely excised. It is however possible that this was not always the case, and thus, some
subsequent surgeries could be the result of endometriosis persistence instead of endometriosis
recurrence. The same applies to the endometriosis subtype with some misdiagnosed at the initial
surgery. Moreover, we cannot exclude that selection bias due to the tertiary nature of our clinic was
in part a reason for the high proportion of patients with endometriosis progression since less severe
endometriosis subtypes may have been surgically treated in other hospitals. However, the tendency of
endometriosis progression was observed also on the patients exclusively treated in our clinic. Finally,
we lacked reliable data on postoperative hormonal medication. Although there is a consistency of
prescription within the single clinic, it is impossible to confirm compliance. We could assume, however,
that since the time to recurrence was not statistically significantly different between groups, there was
also no significant difference in the hormonal medication used.
The main advantages of the current study should also be mentioned. It provides real world data
and contrary to available studies, a very long follow-up, often including the whole reproductive time,
traversing many recurrent surgeries per patient. Moreover, recurrences are well defined and described
by laparoscopy, not by imaging alone, adding to the accuracy of the observations. Finally, the inclusion
of all hospital-based recurrent patients provides more generalizability compared to the population
included in available RCTs primarily designed for other purposes.
The results of the study will help clinicians to better comprehend the evolution of endometriosis
in recurrent surgeries and ultimately provide valuable information for patient counselling, especially
after surgery.
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